Immunexpress Looks To Leverage U.S. Anti-Infection Incentives With Unique Sepsis Diagnostic
This article was originally published in The Gray Sheet
Executive Summary
The Seattle company's SeptiCyte system is designed to directly quantify molecular markers of sepsis from patient blood samples and tell doctors the probability that a patient has sepsis within four hours, allowing for aggressive treatment of sepsis or, if the test result is negative, preventing unnecessary antibiotics.